Elixinol Share Price Gets Small Boost on Turnaround (ASX:EXL)

By ,

After a ripper period in early 2019, the Elixinol Global Ltd [ASX:EXL] share price went on a long-term slide.

You can see what this looks like on the EXL share price chart below:

ASX EXL Share Price Chart - Elixinol Share Price

Source: tradingview.com

On a day where the EXL share price was up 3.33% to trade at 15.5 cents, we take a look at the numbers from EXL quarterly update.

EXL share price chart in context of latest numbers

After the heady days of early 2019, Elixinol now has a market cap of less than $30 million.

I’ve seen charts like this before — they can be a grim omen.

But there are a couple (small) rays of light at the end of the tunnel for Elixinol.

Here are the headline numbers from their latest quarterly:

  • Q3 FY2020 revenue 1 of $4.0m – 18% quarter on quarter improvement vs Q2 FY2020 of $3.4m, exceeding the previous guidance of 10-15% growth
  • Cost reduction measures implemented in H1 FY2020 have reduced net cash used in operating activities in Q3 FY2020 to $3.5m – down from $6.2m in Q2 FY2020 and down from $9.0m in Q1 FY2020

So, a small revenue guidance beat, and costs coming down.

Looking at the other numbers in the quarterly, you can see it has $12.7 million cash on hand as well.

Outlook for EXL share price

Elixinol has faced a long string of challenges, and their ability to surmount them will determine its future.

A progressive reduction of operating expenses helps, but I’d say that revenue growth is also really important in addition to simply bringing costs down.

They are now a retail presence in Ireland and the UK, which complements their ecommerce pivot.

It may be a long wait for an EXL share price renaissance.

Or it may not occur at all.

Given prior experience, the EXL share price chart indicates that those still clinging on may be resigned to an all-or-nothing outcome.

Regards,

Lachlann Tierney

For Money Morning

PS: Four Well-Positioned Small-Cap Stocks — These innovative Aussie companies are well placed to capitalise on post-lockdown megatrends. Click here to learn more.

About Lachlann Tierney

Lachlann Tierney is an Analyst for Money Morning and has been investing for nearly a decade. With a Masters of Science from the London School of Economics, he brings a sound understanding of global markets to his writing. Lachlann is interested in emerging technologies, energy solutions and helping people invest…

Incannex Healthcare Shares Up on Arthritis Treatment Test (ASX:IHL)

Incannex Healthcare share price [ASX:IHL] is up today after its ASX update shows positive results from IHL’s arthritis treatment test. The Incannex share price is up 9.7% as of 3:00pm today…

Elixinol Share Price Up 12% after Acquiring CannaCare Health (ASX:EXL)

Elixinol Global Ltd [ASX:EXL] share price is up today after agreeing to acquire Germany’s leading CBD brand. The EXL share price is now up 25% YTD, but still down from the 52-week high of 47.5 cents.

Elixinol Share Price Down: Two Thoughts on its Future

After going to almost $6 a share, it is going for almost a tenth of this price today. We look at what has happened to the Elixinol share price and the company’s restructure.

Why ASX Cannabis Stocks are Down — Should You Invest?

It’s been a tough year for ASX cannabis stocks with many companies shedding value over a 12-month window. Only Althea has emerged from the last year with a gain to show for it. It’s worth taking a look at the ETFMG Alternative Harvest ETF chart to see what’s happening to cannabis stocks globally….

Elixinol Share Price Up as US Warms to Cannabis (ASX: EXL)

Cannabis and hemp are back in the US headlines. And one local pot stock — Elixinol — is feeling a high…share price. At time of writing Elixinol Global Ltd [ASX:EXL] is up 11%. Though it did peak even higher at a 12.28% gain prior in early trading…

ASX Cannabis Stocks Wrap: MGC, BDA Elixinol News

Today, we look at the latest Elixinol news, along with recent announcements out of MGC and BOD. We conclude that Elixinol could encounter support in the coming weeks or months. Meanwhile, MGC and BOD remain exciting but more speculative cannabis plays.